PMID- 19133135
OWN - NLM
STAT- MEDLINE
DCOM- 20090219
LR  - 20211020
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 7
DP  - 2009 Jan 8
TI  - Semi-allogeneic vaccines and tumor-induced immune tolerance.
PG  - 3
LID - 10.1186/1479-5876-7-3 [doi]
AB  - Experimental results from studies with inbred mice and their syngeneic tumors 
      indicated that the inoculation of semi-allogeneic cell hybrids (derived from the 
      fusion between syngeneic tumor cells and an allogeneic cell line) protects the 
      animal host from a subsequent lethal challenge with unmodified syngeneic tumor 
      cells. Semi-allogeneic somatic cell hybrids were generated by the fusion of EL-4 
      T lymphoma cells (H-2b) and BALB/c-derived renal adenocarcinoma RAG cells (H-2d). 
      Cell hybrids were injected intra-peritoneally (i.p.) in C57BL/6 mice (H-2b) 
      before challenging the mice with a tumorigenic dose of EL-4 cells. 
      Semi-allogeneic tumor cell hybrids could not form a tumor in the animal host 
      because they expressed allogeneic determinants (H-2d) and were rejected as a 
      transplant. However, they conferred protection against a tumorigenic challenge of 
      EL-4 cells compared to control mice that were mock-vaccinated with i.p.-injected 
      phosphate-buffered saline (PBS) and in which EL-4 lymphomas grew rapidly to a 
      large size in the peritoneal cavity. Screening of spleen-derived RNA by means of 
      focused microarray technology showed up-regulation of genes involved in the 
      Th-1-type immune response and in the activation of dendritic antigen-presenting 
      cells (APC). The results of our studies confirm the role of APC in mediating the 
      immune protection induced by semi-allogeneic vaccines by activating a Th-1 
      response; these studies also reveal that semi-allogeneic vaccines are able to 
      interfere with or even block the tumor-mediated induction of immune tolerance, a 
      key mechanism underlying the suppression of anti-tumor immunity in the immune 
      competent host.
FAU - Yu, Jin
AU  - Yu J
AD  - Department of Radiation Oncology, Medical University of South Carolina, 
      Charleston, SC 29425, USA. yujin@musc.edu
FAU - Kindy, Mark S
AU  - Kindy MS
FAU - Gattoni-Celli, Sebastiano
AU  - Gattoni-Celli S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20090108
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
RN  - 0 (Vaccines)
SB  - IM
MH  - Animals
MH  - Cell Line
MH  - Clonal Anergy
MH  - Gene Expression Regulation
MH  - Humans
MH  - Hybrid Cells/*immunology
MH  - Immune Tolerance/*immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Survival Rate
MH  - Th1 Cells/immunology
MH  - Vaccines/*immunology
PMC - PMC2631475
EDAT- 2009/01/10 09:00
MHDA- 2009/02/20 09:00
PMCR- 2009/01/08
CRDT- 2009/01/10 09:00
PHST- 2008/10/17 00:00 [received]
PHST- 2009/01/08 00:00 [accepted]
PHST- 2009/01/10 09:00 [entrez]
PHST- 2009/01/10 09:00 [pubmed]
PHST- 2009/02/20 09:00 [medline]
PHST- 2009/01/08 00:00 [pmc-release]
AID - 1479-5876-7-3 [pii]
AID - 10.1186/1479-5876-7-3 [doi]
PST - epublish
SO  - J Transl Med. 2009 Jan 8;7:3. doi: 10.1186/1479-5876-7-3.